Clinical Trial Update: Efficacy of Remission-induction Regimen With Infliximab for Severe Extrathoracic Sarcoidosis (EFIRTES) [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating a remission-induction regimen with infliximab for severe extrathoracic sarcoidosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extrathoracic Sarcoidosis

Drugs mentioned

• Infliximab (infliximab)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Extrathoracic Sarcoidosis | Phase 3 | Status: COMPLETED